首页 > 市场调查报告书 > 製药

癌症生物製剂

癌症免疫疗法市场规模、份额和成长分析（按类型、应用、给药途径、最终用户和地区划分）—产业预测，2026-2033年

市场调查报告书

商品编码

1898321

癌症免疫疗法市场规模、份额和成长分析（按类型、应用、给药途径、最终用户和地区划分）—产业预测，2026-2033年

Cancer Immunotherapy Market Size, Share, and Growth Analysis, By Type (Monoclonal Antibodies, Cancer Vaccines), By Application (Lung Cancer, Breast Cancer), By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 197 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球癌症免疫疗法市场规模将达到 1,359.3 亿美元，到 2025 年将达到 1,473.5 亿美元，到 2033 年将达到 2,809.2 亿美元，预测期（2026-2033 年）的复合年增长率为 8.4%。

全球癌症免疫疗法市场正经历显着扩张，这主要得益于癌症发病率的上升、标靶治疗需求的增长以及免疫肿瘤学技术的进步。免疫查核点抑制剂，尤其是PD-1/PD-L1和CTLA-4抑制剂，已展现优于传统治疗方法的疗效。个人化医疗和CAR-T疗法重新定义了癌症治疗策略，并在多种癌症类型中取得了持续的疗效。强大的研发投入、有利的监管环境以及不断加强的公私合营，正在推动快速创新，尤其是在黑色素瘤和肺癌等难治性恶性肿瘤领域。然而，不断上涨的治疗成本、低收入地区治疗资源的匮乏以及严重的免疫相关不利事件仍然是巨大的挑战。儘管如此，人工智慧的融入正在革新患者筛选和治疗优化，旨在实现更有效、更公平的癌症治疗方案。

全球癌症免疫疗法市场驱动因素

全球免疫肿瘤市场的成长主要受全球各类癌症发生率上升的驱动。癌症作为全球健康挑战的主要因素，其日益增长的盛行率凸显了对创新有效治疗方法的迫切需求。肺癌、乳癌、大肠癌、黑色素瘤和血液相关恶性肿瘤等癌症持续影响着相当大比例的人口，因此，对先进治疗方案的需求变得愈发迫切。这种情况凸显了开拓创新策略以应对日益严重的全球癌症负担并改善患者预后的重要性。

全球癌症免疫疗法市场面临的限制因素

癌症发生率的指数级增长促使人们更加关注癌症治疗，尤其是免疫疗法的研发。随着这些治疗方法的生产和测试规模的扩大，其相关费用往往令患者难以承受，成为市场成长的一大障碍。此外，免疫疗法的一些副作用，例如肿胀、皮疹、心悸和头痛，也会使患者放弃治疗。这种犹豫进一步阻碍了癌症免疫疗法市场的潜在扩张，凸显了解决经济和安全问题以促进这些治疗方法更广泛接受和应用的必要性。

全球癌症免疫疗法市场趋势

全球免疫肿瘤市场的一大趋势是整合个人化医疗策略。治疗方法根据个体的基因谱和肿瘤特征量身定制，从而提高疗效并最大限度地减少副作用。这推动了对创新生物标记驱动治疗方法的需求。此外，将免疫疗法与化疗和标靶治疗等传统疗法结合的联合治疗疗法也日益普及。对多种癌症类型的日益关注以及包括CAR-T细胞疗法和免疫查核点抑制剂在内的新型药物製剂的出现，进一步塑造了市场格局，从而改善患者预后并增加研发投入。

Merck & Co., Inc.（USA）
Bristol-Myers Squibb Company（USA）
F. Hoffmann-La Roche AG（Switzerland）
AstraZeneca plc（UK）
Regeneron Pharmaceuticals, Inc.（USA）
Gilead Sciences, Inc.（USA）
Novartis AG（Switzerland）
Pfizer Inc.（USA）
Amgen Inc.（USA）
Johnson & Johnson（USA）
BioNTech SE（Germany）
Moderna, Inc.（USA）
Exelixis, Inc.（USA）
Alnylam Pharmaceuticals, Inc.（USA）
Incyte Corporation（USA）
Sanofi SA（France）
BeiGene, Ltd.（China）
Zai Lab Limited（China）
Fate Therapeutics, Inc.（USA）
Kura Oncology, Inc.（USA）

结论与建议

简介目录

Product Code: SQMIG35H2344

Global Cancer Immunotherapy Market size was valued at USD 135.93 Billion in 2024 and is poised to grow from USD 147.35 Billion in 2025 to USD 280.92 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).

The global Cancer Immunotherapy market is witnessing significant expansion driven by increasing cancer prevalence, a growing preference for targeted therapies, and advancements in immuno-oncology technologies. Immune checkpoint inhibitors, notably PD-1/PD-L1 and CTLA-4, are proving more effective than traditional treatments. Personalized medicine and CAR-T therapies are redefining treatment approaches, delivering sustainable results for various cancer types. Strong research and development efforts, coupled with favorable regulatory landscapes and enhanced public-private collaborations, are facilitating rapid innovation, especially for challenging malignancies like melanoma and lung cancer. However, high treatment costs, limited accessibility in low-income regions, and severe immune-related adverse effects pose considerable challenges. Nevertheless, the integration of artificial intelligence is revolutionizing patient selection and treatment optimization, ultimately aiming for more effective and equitable cancer care solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Immunotherapy Market Segments Analysis

Global Cancer Immunotherapy Market is segmented by Type, Application, Route of Administration, End User and region. Based on Type, the market is segmented into Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma and Others. Based on Route of Administration, the market is segmented into Intravenous (IV), Intramuscular and Oral. Based on End User, the market is segmented into Hospitals & Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Immunotherapy Market

The growth of the global cancer immunotherapy market is primarily driven by the increasing incidence of various cancer types across the globe. The escalating prevalence of cancer, which stands as a leading contributor to global health challenges, underscores the urgent demand for innovative and effective treatment methods. As cancers such as lung, breast, colorectal, melanoma, and blood-related malignancies continue to impact a significant portion of the population, the necessity for advanced therapeutic solutions becomes increasingly critical. This context emphasizes the importance of pioneering new strategies to tackle the rising global cancer burden and improve patient outcomes.

Restraints in the Global Cancer Immunotherapy Market

The rapid rise in cancer prevalence has intensified the focus on research and development in cancer treatments, particularly immunotherapy. As the production and testing of these therapies expand, the associated costs often become prohibitively high for patients, posing a significant barrier to market growth. Additionally, the various side effects linked with immunotherapy, including swelling, skin rashes, heart palpitations, and headaches, can deter patients from pursuing these treatments. This reluctance further undermines the potential expansion of the cancer immunotherapy market, highlighting the need to address both financial and safety concerns to foster wider acceptance and utilization of these therapies.

Market Trends of the Global Cancer Immunotherapy Market

A key market trend in the global cancer immunotherapy landscape is the increasing integration of personalized medicine strategies, as therapies are tailored to individual genetic profiles and tumor characteristics. This approach enhances treatment efficacy and minimizes adverse effects, driving demand for innovative biomarker-driven therapies. Additionally, the expansion of combination therapies, utilizing immunotherapies alongside traditional treatments like chemotherapy and targeted therapies, is gaining traction. The growing focus on addressing various cancer types and the rise of novel drug formulations, including CAR-T cell therapies and immune checkpoint inhibitors, are further shaping the market, leading to improved patient outcomes and heightened investment in research and development.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Cancer Immunotherapy Market Size by Type & CAGR (2026-2033)

Market Overview
Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators

Global Cancer Immunotherapy Market Size by Application & CAGR (2026-2033)

Market Overview
Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others

Global Cancer Immunotherapy Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intravenous (IV)
Intramuscular
Oral

Global Cancer Immunotherapy Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Cancer Research Centers
Others

Global Cancer Immunotherapy Market Size & CAGR (2026-2033)

North America (Type, Application, Route of Administration, End User)
- US
- Canada
Europe (Type, Application, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, Route of Administration, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene, Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zai Lab Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fate Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kura Oncology, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments